It’s been a crucial week for La Jolla Pharmaceutical Company (NASDAQ:LJPC); here’s what analysts have to say.

February 15, 2018 - By Nellie Frank

 It's been a crucial week for La Jolla Pharmaceutical Company (NASDAQ:LJPC); here's what analysts have to say.
Investors sentiment decreased to 1.61 in 2017 Q3. Its down 0.20, from 1.81 in 2017Q2. It fall, as 10 investors sold La Jolla Pharmaceutical Company shares while 21 reduced holdings. 25 funds opened positions while 25 raised stakes. 23.31 million shares or 1.99% less from 23.78 million shares in 2017Q2 were reported.
Broadfin Capital Lc holds 1.06M shares. Emory University holds 52,754 shares or 1.45% of its portfolio. Susquehanna Int Limited Liability Partnership reported 204,939 shares stake. Barclays Public Limited owns 9,993 shares for 0% of their portfolio. Goldman Sachs stated it has 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Fmr Ltd Liability Company stated it has 3.32 million shares. Moreover, Bank & Trust Of New York Mellon Corporation has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Wolverine Asset Mgmt Ltd Liability holds 0.01% or 32,338 shares. State Board Of Administration Of Florida Retirement System holds 11,305 shares or 0% of its portfolio. Nationwide Fund Advisors has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 9,618 shares. Great West Life Assurance Can reported 0% stake. Gsa Prns Limited Liability Partnership reported 8,892 shares. Sectoral Asset owns 601,500 shares. Blackrock holds 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC) or 1.16M shares. Baker Bros Limited Partnership invested in 154,675 shares or 0.04% of the stock.

Since December 29, 2017, it had 0 buys, and 1 insider sale for $323,208 activity.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Among 8 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 5 have Buy rating, 3 Sell and 0 Hold. Therefore 63% are positive. La Jolla Pharmaceutical Company had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, July 24 by Jefferies. The rating was downgraded by Zacks on Tuesday, August 11 to “Hold”. Lake Street initiated La Jolla Pharmaceutical Company (NASDAQ:LJPC) on Tuesday, May 24 with “Buy” rating. JP Morgan downgraded the stock to “Underweight” rating in Friday, December 8 report. The firm earned “Outperform” rating on Tuesday, February 9 by Cowen & Co. The firm has “Buy” rating given on Thursday, August 31 by Jefferies. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, January 30 report. The firm earned “Buy” rating on Friday, December 22 by Cowen & Co. Jefferies maintained La Jolla Pharmaceutical Company (NASDAQ:LJPC) on Monday, June 12 with “Buy” rating. As per Tuesday, September 8, the company rating was maintained by Chardan Capital Markets. Below is a list of La Jolla Pharmaceutical Company (NASDAQ:LJPC) latest ratings and price target changes.

12/02/2018 Broker: Jefferies Old Rating: Buy New Rating: Underperform Downgrade
30/01/2018 Broker: H.C. Wainwright Rating: Buy Maintain
22/12/2017 Broker: Cowen & Co Rating: Buy New Target: $55.0 Maintain
22/12/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $90.0
22/12/2017 Broker: SunTrust Rating: Buy
21/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $62 Initiates Coverage On
08/12/2017 Broker: J.P. Morgan Rating: Sell New Target: $20.0 Downgrade
08/12/2017 Broker: JP Morgan Old Rating: Overweight New Rating: Underweight Old Target: $36 Downgrade
27/10/2017 Broker: Cowen & Co Rating: Buy New Target: $55.0
31/08/2017 Broker: Jefferies Rating: Buy New Target: $40.0 Maintain

The stock decreased 1.64% or $0.535 during the last trading session, reaching $32.195. About 211,595 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 128.65% since February 15, 2017 and is uptrending. It has outperformed by 111.95% the S&P500.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $712.97 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Another recent and important La Jolla Pharmaceutical Company (NASDAQ:LJPC) news was published by Fool.com which published an article titled: “Why Lumber Liquidators Holdings, Stamps.com, and La Jolla Pharmaceutical …” on February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.